Literature DB >> 1517385

The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.

J H Kim1, M M Seibel, D T MacLaughlin, P K Donahoe, B J Ransil, P A Hametz, C J Richards.   

Abstract

This study was undertaken to determine if Müllerian-inhibiting substance (MIS) could block basal and/or epidermal growth factor (EGF)-induced proliferation and progesterone production by cultured human granulosa-luteal cells. Cells from follicles of individual patients were pooled, counted, and aliquoted into Ham's F-10 medium containing 10% MIS-free female fetal calf serum at 37 C in 95% air and 5% CO2. After assessing viability, cells were counted on days 4, 8, 12, and 16 of culture. EGF was added every other day at 0.2, 2, and 20 ng/mL beginning on culture day 4. The greatest stimulatory effect of EGF on cell proliferation was observed at 20 ng/mL on days 12 and 16. EGF increased progesterone production per cell after 4 days exposure, but this effect was lost after 8 days. Granulosa-luteal cells were cultured with 0.2, 2, and 20 ng/mL immunoaffinity purified recombinant human MIS (rhMIS) or conditioned medium from Chinese hamster ovary cells transfected with the human MIS gene, beginning on culture day 4. rhMIS demonstrated its greatest inhibitory effect on cell proliferation at 20 ng/mL on day 16. The rhMIS decreased progesterone production per cell after 4 days exposure, but only in the higher doses. Maintaining EGF at 20 ng/mL and varying rhMIS yielded significant reduction in EGF-mediated proliferation and progesterone production per cell at 2 and 20 ng/mL rhMIS. These experiments demonstrate rhMIS inhibits basal and EGF-stimulated human granulosa-luteal cell proliferation and progesterone production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517385     DOI: 10.1210/jcem.75.3.1517385

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH.

Authors:  Sandro Sacchi; Giovanni D'Ippolito; Paola Sena; Tiziana Marsella; Daniela Tagliasacchi; Elena Maggi; Cindy Argento; Alessandra Tirelli; Simone Giulini; Antonio La Marca
Journal:  J Assist Reprod Genet       Date:  2015-12-02       Impact factor: 3.412

2.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.

Authors:  Henry L Chang; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Xianlin Li; Xiaolong Wei; David T MacLaughlin; Patricia K Donahoe
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

4.  Attenuated AMH signaling pathway plays an important role in the pathogenesis of ovarian hyperstimulation syndrome.

Authors:  Lan Wang; Hemei Li; Jihui Ai; Jing Yue; Zhou Li; Hanwang Zhang; Yiqing Zhao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 5.  Common pathophysiological mechanisms involved in luteal phase deficiency and polycystic ovary syndrome. Impact on fertility.

Authors:  Georgios Boutzios; Maria Karalaki; Evangelia Zapanti
Journal:  Endocrine       Date:  2012-08-29       Impact factor: 3.633

6.  Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Aurelio Barricarte; Louise A Brinton; Brian L Egleston; Roni T Falk; Renée T Fortner; Kathy J Helzlsouer; Yutang Gao; Annika Idahl; Rudolph Kaaks; Vittorio Krogh; Melissa A Merritt; Eva Lundin; N Charlotte Onland-Moret; Sabina Rinaldi; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Carlotta Sacerdote; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley S Tworoger; Kala Visvanathan; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Joanne F Dorgan
Journal:  Int J Cancer       Date:  2017-10-04       Impact factor: 7.396

Review 7.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

8.  Receptors for anti-müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation.

Authors:  C Racine; R Rey; M G Forest; F Louis; A Ferré; I Huhtaniemi; N Josso; N di Clemente
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

9.  Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer.

Authors:  Daniel A Dumesic; Timothy G Lesnick; Jacques P Stassart; G David Ball; Ashley Wong; David H Abbott
Journal:  Fertil Steril       Date:  2009-07       Impact factor: 7.329

10.  BMP15 suppresses progesterone production by down-regulating StAR via ALK3 in human granulosa cells.

Authors:  Hsun-Ming Chang; Jung-Chien Cheng; Christian Klausen; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2013-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.